Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET

Company Participants

Robert Andrade - CFO
Jeffrey Hackman - CEO and Board Member

Conference Call Participants

Chase Knickerbocker - Craig Hallum
Naureen Quibria - Capital One Securities
Raghuram Selvaraju - H.C. Wainwright

Operator

Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Second Quarter 2024 Earnings and Corporate Update Conference Call. [Operator Instructions] As a reminder, today's conference call is being recorded.

Now I'd like to turn the conference over to Fennec's Chief Financial Officer, Robert Andrade. Please go ahead.

Robert Andrade

Thank you, operator, and good morning, everyone. We appreciate you joining us today for Fennec Pharmaceuticals' second quarter 2024 earnings conference call, during which we will review our financial results as well as provide a general business update.

Joining me from Fennec this morning is our newly appointed Chief Executive Officer and Board Member, Jeff Hackman. Jeff joined Fennec on August 5th and brings more than 30 years of commercial leadership including oversight of more than 10 product launches across a wide range of therapeutic areas and markets. Importantly, Jeff has successfully commercialized products that are specifically relevant to the PEDMARK markets.

Now before we begin, I would like to remind you that during this call, the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. References to these risks and uncertainties are made in today's press release and disclosed in detail in the company's periodic and current event filings with the U.S. Securities and Exchange Commission. In addition, any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements.

This conference call is being recorded for audio rebroadcast on Fennec's website, www.fennecpharma.com, where it will be available for the next 30 days.

And now it gives me pleasure to turn the call over to Jeff Hackman.

Jeffrey Hackman

Thank you, Robert, and good morning, everyone.

I'm incredibly excited to lead Fennec in this new role and I look forward to working with this team to direct the organization through its continued growth efforts. Before I introduce myself, I would like to thank Rosty for his dedication and leadership since 2009. He's been critical not only to the success of Fennec, but bringing a much needed therapy to the pediatric oncology population that was at risk for irreversible hearing loss, which can be a profound lifelong impact, as you know, on these patients.